Oxidase

Other Names

No alternative names.

Synopsis

Diamine Oxidase (DAO): A Comprehensive Encyclopedic Reference

1. Nomenclature and Classification

In the context of dietary supplementation and natural health products, the term "oxidase" most specifically refers to diamine oxidase (abbreviated DAO), an enzyme that has gained substantial attention as a dietary supplement for the management of histamine intolerance and related conditions. Diamine oxidase (DAO), also known as amine oxidase, copper-containing, 1 (AOC1) — formerly called histaminase — is an enzyme (EC 1.4.3.22) involved in the metabolism, oxidation, and inactivation of histamine and other polyamines such as putrescine or spermidine. The enzyme belongs to the amine oxidase (copper-containing) (AOC) family of amine oxidase enzymes.

DAO [EC 1.4.3.22] belongs to the copper-containing amine oxidases family and is involved in the oxidative deamination of biogenic amines (primarily histamine), converting them to aldehydes while releasing ammonia and hydrogen peroxide as byproducts. The enzyme classification number EC 1.4.3.22 positions DAO within the oxidoreductase class, acting on the CH–NH₂ group of donors using oxygen as the acceptor — hence the designation "oxidase."

Diamine oxidase (DAO) is a member of the copper-containing amine oxidase (CAO) family of enzymes that are distinguished by the presence of a type II copper ion and a protein-derived trihydroxyphenylalanine quinone (TPQ) cofactor. Three genes, AOC1–3, code for viable CAOs in humans. AOC1 codes for the diamine oxidase enzyme.

2. Identity and Natural Sources

2.1 Chemical and Botanical Identity

Humans have three functioning genes that encode copper-containing amine oxidases. The product of the AOC1 gene is a so-called diamine oxidase (hDAO), named for its substrate preference for diamines, particularly histamine. The homodimeric structure has the archetypal amine oxidase fold. Two active sites, one in each subunit, are characterized by the presence of a copper ion and a topaquinone residue formed by the post-translational modification of a tyrosine.

AOC-1 encodes for a diamine oxidase (DAO), possesses a histamine metabolism activity, and is predominantly found in the kidney, placenta, intestine, thymus, and seminal vesicles. The enzyme is a secretory protein that acts extracellularly, particularly at the luminal surface of the intestinal epithelium.

2.2 Natural Biological Sources

DAO is produced endogenously in humans, but for supplemental purposes it is extracted from both animal and plant sources.

Porcine kidney: DAO supplements contain exogenous DAO, typically derived from porcine kidney extract or plant-based sources. Pig kidney has historically been the predominant source for commercial preparations, as it yields high enzymatic activity.
Legume sprouts (plant-derived): Edible legume sprouts have been proposed as a promising plant-based source of the enzyme diamine oxidase (DAO), which plays a key role in degrading histamine at an intestinal level and preventing the development of histamine intolerance symptoms. Sprouted legumes — particularly from peas (Pisum sativum) and lentils — are among the richest natural sources of exogenous DAO. Lyophilized green pea and grass pea sprouts show the highest DAO activity, followed by lentils, soybeans, and chickpeas. In contrast, lyophilized alfalfa, broad bean, and white lupine sprouts show the lowest enzymatic activity values.
Germination conditions: It has been concluded that certain edible legumes proved to be a source of DAO enzyme, confirming the potential suitability of this food for the formulation of DAO supplements. Germination of legume seeds for 6 days in the dark provided the plant matrix with the maximum histamine-degrading capacity. Pea shoots, lentil sprouts, and mung bean sprouts have been shown to exhibit significant DAO activity — up to 250 times that found in ungerminated seeds, when grown in darkness.

2.3 Commercial Preparations and Forms

Most commercial formulations encapsulate the enzyme to survive gastric acidity and release it in the small intestine. Lyophilised legume sprouts may be a functional ingredient of DAO enzyme supplements. Comas-Basté et al. (2019) analyzed the histamine-degrading activity of various supplements marketed in different countries, all of them formulated with porcine kidney extracts, finding values ranging between 0.04 and 0.20 mU/mg.

Supplement forms available on the market include enteric-coated capsules and tablets, lyophilized powder capsules derived from pea sprouts (for vegetarian consumers), and combined formulations that pair DAO with co-factors such as copper and vitamin B6 to support endogenous enzyme activity. Supplementation with exogenous DAO enzyme of animal origin has received regulatory consideration as a novel food to enhance intestinal degradation of histamine.

3. Biochemistry and Mechanism of Action

3.1 Catalytic Mechanism

Copper amine oxidases (CAOs) catalyze the conversion of primary amines to aldehydes coupled to the reduction of O₂ to H₂O₂. These enzymes utilize a wide range of substrates from methylamine to polypeptides. In the case of DAO specifically, the primary substrate of physiological relevance is histamine.

CAOs contain a cofactor, 2,4,5-trihydroxyphenylalanine quinone (TPQ), that is required for catalytic activity and synthesized through the post-translational modification of a tyrosine residue within the CAO polypeptide. TPQ generation is a self-processing event only requiring the addition of oxygen and Cu(II) to the apoCAO.

DAO [EC 1.4.3.22] belongs to the copper-containing amine oxidases family and is involved in the oxidative deamination of biogenic amines (primarily histamine), converting them to aldehydes while releasing ammonia and hydrogen peroxide as byproducts. The enzymatic activity of DAO is highly dependent on specific cofactors essential for its function. Copper ions (Cu²⁺), calcium ions (Ca²⁺), and topaquinone (TPQ) are recognised as the key cofactors of human DAO. These compounds act by facilitating the oxidation of amines, stabilising intermediate reaction states, and enhancing enzyme stability.

3.2 Physiological Role: The Histamine-Scavenging System

Diamine oxidase (DAO) is a key enzyme responsible for the metabolism of histamine, preventing its excessive accumulation and thereby maintaining physiological homeostasis. Diamine oxidase (DAO) and histamine-N-methyltransferase (HNMT) are the two enzymes in charge of the histamine scavenging system in humans. Due to its intestinal location, DAO is the key enzyme in the degradation of ingested histamine, and its deficit has been suggested to be the main cause of histamine intolerance.

This condition arises primarily from deficient intestinal activity of the enzyme diamine oxidase (DAO), which, by breaking it down, serves as the main barrier to dietary histamine entering systemic circulation. When DAO is deficient, histamine accumulates in the plasma, leading to clinical manifestations of histamine intolerance. Histamine interacts with four types of histamine receptors in the body, with variable physiological effects. Consequently, symptoms resulting from histamine accumulation can impact multiple organs and tissues.

Changes in CAO activity are correlated with a variety of human diseases, including diabetes mellitus, Alzheimer's disease, and inflammatory disorders. This broader pharmacological relevance of the amine oxidase family underscores the importance of DAO beyond its histamine-degrading role in the gut.

3.3 Genetic Encoding and Polymorphisms

The amine oxidase copper-containing 1 (AOC1) gene encodes for the diamine oxidase (DAO) enzyme. DAO is an enzyme that catabolizes some molecules, including histamine, and is the degradative enzyme in the polyamine catabolic pathway that is active in intestinal mucosal cells.

The AOC1 gene is located on chromosome 7q36, and its most relevant nonsynonymous polymorphisms in Caucasian individuals include rs10156191 (p.Thr16Met), rs1049742 (p.Ser332Phe), and rs1049793 (p.His645Asp), which affect enzyme production of DAO, including rs2052129 (G4586T), which is found in the promoter region of the gene and produces lower transcriptional activity. A total of 85 SNPs are located in the human AOC1 gene. Seven of these SNPs produce an amino acid substitution, serving as candidates that cause alterations in the metabolic capacity of the enzyme. Of the polymorphisms found in the AOC1 gene sequence, four have been associated with low enzymatic activity in the metabolism of histamine.

4. Traditional and Historical Use

The concept of an enzyme specifically described as "diamine oxidase" is a product of twentieth-century biochemistry, and as such, DAO as a named, isolated supplement has no ancient or traditional ethnobotanical history in the conventional sense. However, the foods richest in DAO — particularly porcine kidney and germinated legumes — have deep historical uses in various culinary traditions.

Offal including kidney has been consumed across European, Asian, and African cultures for centuries, valued for its high nutrient density. While historical consumers did not conceptualize dietary DAO enzyme content explicitly, the dietary tradition of consuming organ meats and fresh sprouted seeds represents the earliest form of food-based DAO intake.

Pork kidneys remain available as a traditional source of DAO via butchers or specialty markets and can provide a natural dietary supplement in cultures such as the United Kingdom. In traditional herbal and food medicine, germinated seeds (sprouts) were widely used across Asia and the Middle East for their perceived health benefits, though DAO content was not a recognized explanatory mechanism. The formal identification of histaminase (later re-named DAO) as a distinct enzyme occurred in the early twentieth century, and its pharmacological properties were clarified through systematic biochemical research through the latter half of that century.

The modern supplemental use of exogenous DAO to treat histamine intolerance is a clinical-era practice, first emerging in European medical literature in the 1990s and becoming commercially prominent in the 2000s and 2010s, especially in Spain, Germany, and Austria, where academic and clinical interest in histamine intolerance has been particularly active. A plant enzyme which catalyzes the oxidation of aliphatic monoamines and phenylethylamines was identified in research conducted by Werle and Roewer, with the biochemistry of amine oxidases progressively elucidated through the mid-twentieth century.

5. Key Active Constituents and Co-factors

Unlike botanical supplements composed of multiple phytochemical classes, DAO supplements consist of the enzyme protein itself (or a standardized extract containing it), along with its essential biochemical co-factors. The following are established molecular and nutritional constituents relevant to DAO activity:

The DAO protein (hDAO/AOC1 gene product): hDAO has been cloned and expressed in insect cells and the structure of the native enzyme determined by X-ray crystallography to a resolution of 1.8 Å. The protein is a homodimer.
Copper (Cu²⁺): DAO primarily utilizes copper as a cofactor to effectively break down histamine, ensuring that excess histamine does not accumulate and cause adverse reactions. Copper is integral to the active site and required for the generation of the TPQ cofactor.
Topaquinone (TPQ): A post-translationally modified tyrosine residue that forms the organic cofactor within the active site, essential for the oxidative deamination reaction.
Vitamin B6 (pyridoxal phosphate): Several studies have reported that both animal DAO and its related plant enzyme contain pyridoxal phosphate prosthetic groups. Nutritional deficiency of vitamin B6 has been identified as a factor that may suppress DAO activity.
Vitamin C and zinc: The efficiency of DAO can be influenced by nutritional deficiencies, particularly in copper, vitamin B6, and vitamin C, which serve as cofactors for DAO activity. Zinc is additionally referenced in the nutritional literature as supporting DAO function.

6. Scientific Evidence by Area of Use

6.1 Histamine Intolerance (Primary Indication)

Background: Histamine intolerance, also referred to as food histaminosis or food histamine sensitivity, is a disorder in the homeostasis of histamine caused by an imbalance in the degradation of dietary histamine that entails the onset of allergy-like symptoms, occurring even after the ingestion of small amounts of this amine. When DAO activity is insufficient, histamine intolerance (HIT) arises, manifesting as migraines, gastrointestinal disturbances, and allergy-like reactions, among other disorders.

Open-label pilot study (Schnedl et al., 2019, Food Science and Biotechnology): For this open-label interventional pilot study, 28 patients with HIT were identified. For 4 weeks, they were instructed to take DAO capsules before meals. Then, throughout a follow-up period, they were instructed not to take the DAO. A questionnaire included 22 symptoms, divided into 4 categories, as well as a symptom severity score. All symptoms improved significantly during the oral supplementation of DAO. During the follow-up period, without DAO supplementation, the symptoms sum scores increased again. The symptom intensity score was reduced for all symptoms. A significant reduction of every HIT-related symptom and its intensity due to DAO oral supplements was demonstrated. This was an open-label design without a placebo control, which is a significant methodological limitation.

Evidence strength: To date, around twenty studies have investigated the effectiveness of these dietary strategies in reducing the frequency and/or intensity of symptoms, with promising results. However, the limitations of these studies include small patient cohort, lack of control group, and short dietary intervention. Overall, the evidence for DAO supplementation in histamine intolerance is promising but still limited by small study sizes and methodological constraints.

6.2 Migraine and Headache

Background: Histamine intolerance is a disorder in the homeostasis of histamine due to a reduced intestinal degradation of this amine, mainly caused by a deficiency in the enzyme diamine oxidase (DAO). Among histamine-related symptoms, headache is one of the most recorded.

Randomized double-blind trial (Izquierdo-Casas et al., 2019, Clinical Nutrition): 100 patients with confirmed episodic migraine according to current International Headache Society (IHS) criteria and DAO deficiency (levels below 80 HDU/ml) were randomized into two groups. The study found a statistically significant reduction in migraine duration among patients taking DAO supplements, with average pain hours decreasing from 6.14 to 4.76. 1 month of oral DAO enzyme supplementation was verified to reduce pain duration by 1.4 hours in patients with episodic migraine; however, this treatment exerted no significant effect on migraine attack frequency or pain intensity. This study represents one of the more methodologically rigorous human trials of DAO supplementation.

Genetic associations with migraine: García-Martín et al. investigated the association between four SNPs in the AOC1 gene, which are linked to decreased DAO activity, and the susceptibility to developing migraine in a Caucasian Spanish cohort. The study identified the rs10156191 SNP and gender as significant factors in migraine risk. Subgroup analysis revealed that male homozygotes with the rs2052129G allele and female carriers of the rs10156191T allele had a higher risk of developing migraine. Furthermore, the rs10156191T allele, which is associated with reduced DAO enzyme activity, was more prevalent among individuals with migraine, particularly in women.

Evidence strength: The migraine-DAO relationship currently rests on one randomized double-blind trial (n=100) and supporting genetic epidemiological data. The trial demonstrated benefit specifically on attack duration, not frequency or intensity. Evidence is preliminary and further confirmatory studies are needed.

6.3 Fibromyalgia

Background: Fibromyalgia affects 2%–8% of the global population with suboptimal treatment outcomes. Emerging evidence suggests histamine intolerance, mediated by diamine oxidase (DAO) deficiency, may contribute to fibromyalgia pathophysiology in specific patient subgroups. Variants of AOC1 are associated with reduced DAO activity, resulting in accumulation of high levels of histamine and causing a wide range of neurological, gastrointestinal, and epidermal disorders, which are present in people with fibromyalgia.

Genetic prevalence study: Key findings revealed 74.5% prevalence of DAO deficiency-associated genetic variants in fibromyalgia patients vs. 66% in general population (p = 0.014), with cumulative variants correlating with increased symptom severity (~7-point FIQ increase per allele).

Double-blind placebo-controlled clinical trial (Okutan et al., 2023, Journal of Clinical Medicine): Fibromyalgia (FM) is characterized by chronic musculoskeletal pain, muscle tension, joint mobility loss, and several psychological symptoms. Histamine is naturally degraded in the small intestine by DAO. Hereditary or acquired DAO deficiency causes extracellular histamine accumulation, leading to symptoms similar to those of individuals diagnosed with FM. This study aimed to assess the efficacy of adding DAO supplementation for 8 weeks to standard therapy. 100 women with FM (age: 33–61 years) were randomly assigned to the supplementation and control groups. The Fibromyalgia Impact Questionnaire (FIQ), the Pain Catastrophizing Scale (PCS), and intensity scales were applied for a series of clinical symptoms together with the Bristol scale.

Evidence strength: The fibromyalgia–DAO deficiency association is supported by genetic prevalence data and by a 2023 double-blind RCT, making this one of the more actively developing areas of DAO research. Nonetheless, the total body of evidence remains limited, and the mechanistic link between DAO deficiency and fibromyalgia symptomatology requires further validation.

6.4 Insomnia and Sleep Disturbances

Prevalence observational study (2024, MDPI Journal of Clinical Medicine): A total of 167 adult patients (>18 years of age) with symptoms of insomnia underwent genotyping analysis of the four most relevant SNP variants of AOC1. Genetic DAO deficiency was present in 138 patients, with a prevalence rate of 82.6% (95% CI 76–88.1%). This preliminary real-world study presents novel evidence of a potential link between a DAO enzyme deficiency of a genetic origin and clinical symptoms of insomnia, which may suggest the potential benefit of DAO supplementation to improve the quality of sleep in these subjects.

Randomized double-blind placebo-controlled trial on sleep (2025, ScienceDirect): The study patients had alterations of the AOC1 gene, which encodes the DAO enzyme. DAO supplementation improved severe insomnia symptoms, especially sleep efficiency. The DAO supplement showed a potential synergy with melatonin. All these findings may indicate that the use of a dietary DAO supplement, administered once a day at night (20 minutes before dinner), was associated with potential higher benefits especially for improving sleep efficiency.

Evidence strength: The sleep-DAO connection is the most recent and least established area of DAO supplementation research. Current evidence is preliminary, consisting of a prevalence study and a single RCT published in 2025. The findings are intriguing but must be replicated in larger, independent cohorts before conclusions can be drawn.

6.5 Chronic Spontaneous Urticaria

DAO supplementation significantly reduced the duration of migraine attacks (Izquierdo-Casas et al., 2019) and, in another study, caused symptom relief in patients with urticaria (Yacoub et al., 2018). The urticaria study referenced (Yacoub et al., 2018, International Archives of Allergy and Immunology) employed a randomized double-blind placebo-controlled design. Evidence in this indication remains limited to a single small trial and requires corroboration.

7. Body Systems and Health Areas Associated with DAO

Because histamine exerts broad physiological effects through four receptor subtypes (H1, H2, H3, H4) distributed across multiple tissues, DAO deficiency and DAO supplementation have been associated with a correspondingly wide range of body systems:

Gastrointestinal system: If the amount of ingested biogenic amines is high and/or their degradation is inhibited or disturbed in the body, histamine is thought to cause multiple gastrointestinal (GI) symptoms. These may be accompanied by extra-intestinal symptoms including cardiovascular, respiratory, and skin complaints.
Central nervous system / Neurological: Headache, migraine, and associations with cognitive and psychiatric conditions such as ADHD and insomnia have been identified in preliminary studies.
Dermatological: Individuals with histamine intolerance often exhibit reduced DAO activity, leading to the accumulation of histamine in plasma. This can result in diverse symptoms including headaches, flushing, nasal congestion, gastrointestinal upset, urticaria, and in severe cases, pseudo-allergic reactions.
Musculoskeletal system: The preliminary connection between DAO deficiency and fibromyalgia-type pain represents an emerging musculoskeletal association.
Respiratory system: A shortage of the DAO enzyme has been associated with some diseases related to the respiratory, cardiovascular, nervous, muscular, and digestive systems, in addition to migraines.
Sleep architecture: Emerging evidence suggests a role in sleep quality through the histamine–DAO axis in individuals with AOC1 gene polymorphisms.

8. Dosage Forms and Doses Reported in Studies

The following doses are reported as they appear in identified published sources; they do not represent prescriptive recommendations:

Standard commercial dose: The current recommended dose for DAO supplementation is 4.2 mg of DAO extract, three times a day. This dose has shown clinical efficacy in reducing symptoms of histamine intolerance.
Phase I safety trial escalating doses: Thirty participants were randomly assigned to receive single doses of 42 mg, 84 mg, or 210 mg of DAO extract (adiDAO® Veg) or placebo under fasting conditions in a single ascending dose (SAD) design.
Standard extract reference dose in animal safety studies: The doses used in the in vivo animal study represent almost 100-, 500-, and 1000-times the dose of DAO in the commercialized product at a standard dose of 12.6 mg extract/day.
Administration timing: Patients in clinical trials were instructed to take DAO capsules before meals. In the sleep insomnia trial, the dietary DAO supplement was administered once a day at night (20 minutes before dinner).
Duration in trials: Trial durations have ranged from 4 weeks (Schnedl et al., 2019; Izquierdo-Casas et al., 2019) to 8 weeks (Okutan et al., 2023 fibromyalgia trial).

9. Safety Considerations and Interactions

9.1 Clinical Safety Profile

A randomized, double-blind, single ascending dose (SAD) Phase I clinical trial aimed to evaluate the safety and tolerability of escalating doses of DAO supplementation in healthy volunteers. Thirty participants were randomly assigned to receive single doses of 42 mg, 84 mg, or 210 mg of DAO extract (adiDAO® Veg) or placebo under fasting conditions. Vital signs, laboratory parameters, and adverse events (AEs) were monitored. No serious adverse events or clinically significant changes in vital signs, ECGs, or laboratory parameters were observed.

DAO supplementation has shown clinical efficacy in reducing symptoms of histamine intolerance, demonstrating good tolerability and safety.

9.2 Drug Interactions: Compounds That Inhibit Endogenous DAO

A clinically important body of research has evaluated the effects of pharmaceutical drugs on endogenous DAO activity. In vitro studies quantifying inhibition of purified human diamine oxidase found the following:

Chloroquine and clavulanic acid showed the greatest inhibition potential on diamine oxidase (>90%). Cimetidine and verapamil showed inhibition of about 50%. Moderate influence on DAO was caused by isoniazid, metamizole, acetyl cysteine, and amitriptyline (>20%).
Diclofenac, metoclopramide, suxamethonium, and thiamine have very low inhibition potential (<20%). Interestingly, cyclophosphamide and ibuprofen displayed no effect on DAO. Since even levels of about 30% inhibition may be critical, most of the observed substances can be designated as DAO inhibitors.

A separate investigation into the effects of common anti-migraine and anti-inflammatory drugs found nuanced results:

The tested drugs, including ibuprofen, acetylsalicylic acid, paracetamol, a combination of acetylsalicylic acid with paracetamol and caffeine, zolmitriptan, and sumatriptan, did not inhibit DAO activity or reduce their levels. However, naproxen reduced DAO protein levels in human enterocyte cell models, suggesting differential effects among NSAIDs.

DAO supplementation has no known direct interactions with pharmaceutical agents; however, several medications are known to interfere with endogenous DAO activity. These include non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen), and antidepressants, particularly monoamine oxidase inhibitors (MAOIs). While these drugs do not directly interact with exogenous DAO supplements, they may mask or alter the apparent efficacy of supplementation by affecting baseline DAO activity.

9.3 Alcohol and DAO Activity

Ethanol may interfere with enzymatic histamine degradation, but reports on the effects on DAO activity are controversial. There are also conflicting reports whether disulfiram, an FDA-approved agent in the treatment of alcohol dependence, inhibits DAO. In vitro data using recombinant human DAO found that relevant concentrations of ethanol, acetaldehyde, and acetate did not inhibit rhDAO activity in an in vitro assay system. The aldehyde dehydrogenase (ALDH) inhibitors cyanamide and its dimer dicyanamide also had no effect on DAO activity.

9.4 Factors Reducing Endogenous DAO Activity

The efficiency of DAO can be influenced by several factors: genetic polymorphisms in the AOC1 gene (which encodes DAO), chronic intestinal inflammation (e.g., Crohn's disease, celiac disease), medications that inhibit DAO (such as NSAIDs, certain antidepressants, and antihypertensives), and nutritional deficiencies, particularly in copper, vitamin B6, and vitamin C, which serve as cofactors for DAO activity.

9.5 Special Populations

DAO supplementation in children has not been extensively studied. The existing clinical trials have primarily enrolled adults, with several focusing specifically on adult women (particularly in fibromyalgia studies). No robust safety data in pediatric populations, pregnant women, or lactating individuals has been identified in the peer-reviewed literature.

9.6 Limitations of Exogenous DAO Supplementation

DAO supplements are not a panacea. They do not address histamine produced internally due to mast cell activation or allergic reactions. Furthermore, variability in supplement quality, dosing standardization, and labeling accuracy remains an issue in the nutraceutical market.

Current challenges include the lack of standardized diagnostic methods, limitations in supplementation efficacy, and gaps in the regulatory framework.

10. Regulatory Status

Supplementation with exogenous DAO enzyme of animal origin has received the green light as a novel food to enhance intestinal degradation of histamine in the European regulatory context. In the United States, DAO supplements are sold as dietary supplements under the framework of the Dietary Supplement Health and Education Act (DSHEA) and are not approved by the FDA to treat, cure, or prevent any disease. No major national pharmacopoeia (USP, European Pharmacopoeia, or WHO monograph) had published a formal monograph specifically for DAO as a supplement as of the time of the studies reviewed.

11. Summary of Evidence Quality

The weight of available clinical evidence for DAO supplementation can be summarized as follows:

Histamine intolerance (general symptoms): Positive signals from approximately twenty studies including one open-label pilot trial (n=28), but methodological limitations (lack of controls, small cohorts) prevent firm conclusions.
Migraine / headache: Supported by one randomized double-blind trial (n=100) showing significant reduction in headache duration but not attack frequency or pain intensity. Evidence is preliminary.
Fibromyalgia: Supported by genetic prevalence data and one 2023 double-blind RCT (n=100). Evidence is emerging but not yet sufficient for clinical guideline inclusion.
Insomnia / sleep: Preliminary observational evidence (n=167 prevalence study) and one 2025 RCT. Evidence is early-stage and requires replication.
Urticaria: One small randomized trial reported benefit; evidence base is insufficient for firm conclusions.

Across all areas, the overall body of clinical evidence for DAO supplementation is preliminary to moderate. The biological mechanism is well-established at the biochemical level; the clinical translation of this mechanism into supplemental benefit is supported by early trials but has not yet been established to the standard of large, multi-center, independently replicated RCTs.

References

Health Conditions

Health conditions that Oxidase may help support.

No conditions available.

Body Systems

Body systems that Oxidase may help support.

No body systems available.